# Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

> **NCT03730129** · PHASE2,PHASE3 · COMPLETED · sponsor: **Rochester General Hospital** · enrollment: 20 (actual)

## Conditions studied

- Secondary Immune Deficiency Disorder

## Interventions

- **DRUG:** Hizentra

## Key facts

- **NCT ID:** NCT03730129
- **Lead sponsor:** Rochester General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-05
- **Primary completion:** 2020-07-03
- **Final completion:** 2020-07-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03730129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03730129, "Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03730129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*